Abstract
Case reports and epidemiological retrospective case control studies suggested an increased cardiovascular risk associated with the oral contraceptive pill (OC) soon after its introduction; These findings prompted the initiation of three large epidemiological prospective cohort studies: in the United Kingdom those of the Royal College of General Practitioners (RCGP) and the Oxford Family Planning Association and in the United States the Walnut Creek Contraceptive Study. All started in 1968, at a time when older high-dose preparations were those commonly used [1, 2, 3].
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Layde P, Beral V (1981) Further analyses of mortality in oral contraceptive users. Lancet l(8219):541–546
Petitti DB et al. (1979) Risk of vascular disease in women smoking, oral contraceptives, noncontraceptive estrogens, and other factors. JAMA 242 11:1150–1154
Vessey MP, McPherson K, Yeaytes D (1981) Mortality in oral contraceptive users. Lancet 1 (8219): 549–550
Engel HJ, Engel E, Lichtlen P (1985) Koronarsklerose und Herzinfarkt bei jungen Frauen. Muench Med Wochenschr 127, 16:415–417
Mann JI, Inman WHW (1975) Oral contraceptives and death from myocardial infarction. Br Med J [Clin Res] 2:245–248
Hoppe G (1986) The pill, the heart and HDL: facts and fictions. Adv Contracept 2, 3:405–411
Vessey M et al. (1986) Oral contraceptives and venous thromboembolism: findings in a large prospective study. Br Med J [Clin Res] 292, 6519:526
Vessey MP, Lawless M, Yeates D (1984) Oral contraceptives and stroke: findings in a large prospective study. Br Med J [Clin Res] 289 (6444):530–531
Porter JB, Hunter JR, Danillson DA, Jick H, Stergachis A (1982) Oral contraceptives and nonfatal vascular disease - recent experience. Obstet Gynecol 59:299–302
Porter JB, Hunter JR, Jick H, Stergachis A (1985) Oral contraceptives and nonfatal vascular disease. Obstet Gynecol 66, 1:1–4
Khaw Kay-Tee, Peart WS (1982) St. Mary’s Hospital Medical School, London, U.K. Blood pressure and contraceptive use. Br Med J [Clin Res] 285:403–407
Ottossen U-B (1984) Oral progesterone and estrogen-progestogen therapy. Acta Obstet Gynecol Scand [Suppl] 127:1–37
Varma TR (1983) Effect of oestrogen replacement therapy on blood coagulation factors in postmenopausal women. Int J Gynaecol Obstet 4, 21:291–296
Larsson-Cohn U, Fahraens L, Wallentin L, Zador G (1981) Lipoprotein changes may be minimized by proper composition of a combined oral contraceptive. Fertil Steril 35, 2:172–179
Cullberg G, Dovre P, Lindstedt G, Steffensen K (1982) On the use of plasma proteins as indicators of the metabolic effects of combined oral contraceptives. Acta Obstet Gynecol Scand [Suppl] 111:47–54
Losert W, Casals-Stenzel J, Buse M (1985) Progestogens with antimineralocorticoid activity. Arzneimittelforschung 35 (1), 2:459–471
Wambach G (1986) Wie beeinflussen Gestagene den Natriumhaushalt? Fortschr Med 104, 29:37–40
Bruni V et al. (1986) Proceedings 1st International Congress on Gynecology and Endocrinology Madonna di Campiglio.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1988 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Hoppe, G. (1988). Gestoden: An Innovative Progestogen. In: Runnebaum, B., Rabe, T., Kiesel, L. (eds) Female Contraception. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-73790-9_13
Download citation
DOI: https://doi.org/10.1007/978-3-642-73790-9_13
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-73792-3
Online ISBN: 978-3-642-73790-9
eBook Packages: Springer Book Archive